ANPEP and systemic lupus erythematosus: The glycolysislactate_low group showed significant upregulation of most 21 pathways associated with ICB treatment efficacy, except cytokine-cytokine receptor interaction, systemic lupus erythematosus and APM signal pathways (Figure 6H).